News December 3, 2018 Roche buys U.S. biotech Jecure in race for liver disease drugs Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in… Super User 0 Love0
News December 3, 2018 Small Business Innovation Research Program Phase I – NSF – National Science Foundation The National Science Foundation's Small Business Innovation Research (SBIR) program- also known as America's Seed… Super User 0 Love0
News December 3, 2018 Top 10 Pharma Companies of 2018 – GEN Unlike their biotech counterparts, pharmaceutical companies have largely surpassed analyst expectations on earnings per share… Super User 0 Love0
News December 3, 2018 Rise of the Global Startup City America’s long-held singular dominance of startup and venture capital activity is being challenged by the… Super User 0 Love0
News December 3, 2018 Six Things to Consider When Choosing a Location for Your Bio Business – Maryland Business News Driven by breakthrough research and innovation, biohealth and life science are high-risk, high-expense fields. The… Super User 0 Love0
News December 3, 2018 The Real Threat Of Identity Theft Is In Your Medical Records, Not Credit Cards The 2017 holiday season has been complicated by data breaches that have plagued consumers all… Super User 0 Love0
News December 3, 2018 HHS selects 15 tech leaders to discuss healthcare innovation, investment – Health Data Management The Department of Health and Human Services has picked 15 technology leaders from the private… Super User 0 Love0
News December 3, 2018 REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the… Super User 0 Love0
News December 3, 2018 Huge Breakthrough, Huge Controversy: Researcher in China Edits Human Embryo Genes | BioSpace He Jiankui, a researcher in Shenzhen, China, claims he utilized CRISPR-Cas9 gene editing to alter the DNA of… Super User 0 Love0